These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 37459794

  • 1. A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.
    Al-Hashel J, Ahmed SF, AlMojel M, Alroughani R.
    Clin Neurol Neurosurg; 2023 Sep; 232():107885. PubMed ID: 37459794
    [Abstract] [Full Text] [Related]

  • 2. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R, Al-Hashel J, Ahmed SF.
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [Abstract] [Full Text] [Related]

  • 3. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
    Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, Harari G, Flechter S, Achiron A.
    J Neuroimmunol; 2022 Nov 15; 372():577966. PubMed ID: 36162338
    [Abstract] [Full Text] [Related]

  • 11. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G, Rush C, Atkins HL, Freedman MS.
    Mult Scler Relat Disord; 2021 Jul 15; 52():102945. PubMed ID: 33901969
    [Abstract] [Full Text] [Related]

  • 12. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study).
    Arena S, Chisari CG, Toscano S, Bucello S, Grimaldi LM, Ragonese P, Realmuto S, Cottone S, Maimone D, Finocchiaro C, Reitano P, Patti F.
    Curr Neuropharmacol; 2024 Jul 15; 22(7):1271-1283. PubMed ID: 36946484
    [Abstract] [Full Text] [Related]

  • 13. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr 15; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
    López-Real AM, Gonzalez I, Solar DM, Oterino A, Costa E, Pato A, Llaneza MA, García-Estévez DA, Rodriguez-Regal A, Rodriguez M, Peña J.
    Mult Scler Relat Disord; 2023 Jul 15; 75():104762. PubMed ID: 37229800
    [Abstract] [Full Text] [Related]

  • 15. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    Adamec I, Brecl Jakob G, Rajda C, Drulović J, Radulović L, Bašić Kes V, Lazibat I, Rimac J, Cindrić I, Gržinčić T, Abičić A, Barun B, Gabelić T, Gomezelj S, Mesaroš Š, Pekmezović T, Klivényi P, Krbot Skorić M, Habek M.
    J Neuroimmunol; 2023 Sep 15; 382():578164. PubMed ID: 37536052
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
    Santos M, Sequeira J, Abreu P, Guerreiro R, Santos M, Ferreira J, Brum M, Ladeira F, Leitão L, Dias R, Sá MJ, Salgado V, Capela C, de Sá J.
    Clin Neuropharmacol; 2023 Sep 15; 46(3):105-111. PubMed ID: 37191564
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 20. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, Shaw C, Skibina O, Vucic S, Shuey N, Barnett MH, Parratt J, Butzkueven H, Jack D, Fabris J, Kalincik T.
    Mult Scler; 2021 Mar 25; 27(3):465-474. PubMed ID: 32530363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.